Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05328167 · ClinicalTrials.gov registry record · Phase 2
Contrast-Enhanced Ultrasound for the Prediction of Bile Duct Cancer Response to Radioembolization Treatment
A Phase 2 study, sponsored by Thomas Jefferson University.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT05328167 is a Phase 2 study that has completed, run by Thomas Jefferson University. The registered enrollment target is 16 participants.
The verdict
NCT05328167, a Phase 2 study, has completed, sponsored by Thomas Jefferson University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
This phase II trial tests whether contrast-enhanced ultrasound can predict the response of bile duct cancer to targeted radiotherapy (radioembolization treatment). Contrast-enhanced ultrasound uses gas microbubbles that may provide enhancement on ultrasound. It is also possible to pop these microbubbles using ultrasound imaging. Tumors that experience popping of these microbubbles may be easier to kill with radiotherapies. Therefore, this trial may also help doctors see if ultrasound-triggered microbubble popping can improve bile duct cancer response to radiotherapy. Another purpose of this trial is to test if the pressure inside the tumor estimated through ultrasound can be used to predict the tumor response to radiotherapy.
Interventions
- PROCEDURE Contrast-Enhanced Ultrasound
- DRUG Perflutren Protein-Type A Microspheres
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2021-12-14 |
| Est. Completion | 2025-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05328167
The ClinicalTrials.gov registry entry for NCT05328167 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Thomas Jefferson University, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Contrast-Enhanced Ultrasound is the first listed.
NCT05328167 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05328167 about?
NCT05328167 is a clinical study titled "Contrast-Enhanced Ultrasound for the Prediction of Bile Duct Cancer Response to Radioembolization Treatment". This phase II trial tests whether contrast-enhanced ultrasound can predict the response of bile duct cancer to targeted radiotherapy (radioembolization treatment). Contrast-enhanced ultrasound uses gas microbubbles that may provide enhancement on ultrasound. It is also possible to pop these microbub...
What is the current status of trial NCT05328167?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2021-12-14. Estimated completion is 2025-08-31.
What interventions are being tested in trial NCT05328167?
The interventions under investigation include: Contrast-Enhanced Ultrasound (PROCEDURE), Perflutren Protein-Type A Microspheres (DRUG).
Who is sponsoring clinical trial NCT05328167?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.